REGN

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. The Company's commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and rare diseases. It helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through research initiatives, such as Regeneron Genetics Center. It operates gene therapy programs targeting different forms of congenital, monogenic hearing loss. Its advanced clinical-stage candidate is DB-OTO, which is an investigational cell-selective, adeno-associated virus (AAV) gene therapy.